Nautilus Biotechnology, Inc. (NAUT) — Stock Score Summary

Nautilus Biotechnology, Inc. (NAUT) has a MoatMap StockRank of 36/100 based on Quality (36/100), Value (38/100), and Momentum (48/100) factor scores. The current signal is HOLD. An early-stage proteomics platform company with no meaningful revenues and high cash burn. This is a speculative venture-style bet that completely violates our Terry Smith quality compounder and Buffett margin of safety principles.

Nautilus Biotechnology, Inc. is a biotechnology company developing a transformative single-molecule protein analysis platform designed to revolutionize proteomics through ultra-sensitive, high-throughput, and quantitative protein detection. The company's competitive moat is based on its proprietary protein sequencing technology, which holds the potential to provide unprecedented insights into the proteome, thereby significantly advancing biological research and drug discovery. Nautilus is an innovative, early-stage player with the ambition to disrupt the proteomics market.

Key Financial Metrics

Price$2.35
Market Cap$330M
P/E (Forward)-3.62
Price/Book2.36
Return on Equity-33.7%
Return on Invested Capital-36.5%
Debt/Equity19.99
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-29M

Nautilus Biotechnology, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Nautilus Biotechnology, Inc.’s (NAUT) StockRank?
MoatMap’s StockRank for Nautilus Biotechnology, Inc. (NAUT) is 36/100, with a Hold signal. It is a composite of Quality (36), Value (38), and Momentum (48) factor ranks across MoatMap’s 19,000+ stock universe.
Does Nautilus Biotechnology, Inc. have an economic moat?
Nautilus Biotechnology, Inc. (NAUT) has a Quality factor score of 36/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Nautilus Biotechnology, Inc. a buy, hold, or sell?
MoatMap’s current signal for Nautilus Biotechnology, Inc. (NAUT) is Hold, based on a StockRank of 36/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Nautilus Biotechnology, Inc. in?
Nautilus Biotechnology, Inc. (NAUT) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksNAUT deep dive reportAI ChampionsHow we score stocksSense-check another stock